Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies

Use of metformin is associated with a decreased risk of HCC in diabetic patients in a dose-dependent manner, via inhibition of hepatoma cells proliferation and induction of cell cycle arrest at G0/G1 phase.